Advanced Heart Care, LLC | Bridgewater, NJ

Research site

(Unclaimed)

Location

1200 Route 22 East, 3rd floor, Suite 17, Bridgewater, New Jersey, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

BI 690517

Bococizumab

Ziltivekimab

BELVIQ

Omecamtiv Mecarbil

Lorcaserin HCl

EVOLocumab

Survodutide

Vicadrostat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 21 total trials

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting

Obesity

Drug: Placebo

Drug: survodutide

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Begins enrollment this month

Heart Failure

Drug: Placebo matching vicadrostat

Drug: Empagliflozin

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: vicadrostat

Drug: Empagliflozin

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Enrolling

Acute Myocardial Infarction (AMI)

Cardiovascular Risk

Drug: Ziltivekimab

Drug: Placebo

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipi...

Active, not recruiting

Stroke

Myocardial Infarction

Drug: Evolocumab

Drug: Routine Lipid Management

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI)

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only

Acute Myocardial Infarction

Combination Product: Placebo

Combination Product: Selatogrel

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, l...

Enrolling

Heart Failure With Reduced Ejection Fraction

Heart Failure

Drug: Placebo

Drug: Omecamtiv Mecarbil (OM)

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Active, not recruiting

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)